Humana Inc. HUM
Healthcare · Healthcare Plans · United States · S&P 500
Based on the available data, Humana Inc. gets an algorithmic score of 68/100. It trades at 386.87 $, with a bullish technical trend (RSI 49.1) and 47.2% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (11.8% compound annual).
- Low beta (0.39): defensive profile.
- Meaningful dividend (92.00%).
Weaknesses
- Thin net margin (0.9%): vulnerable to costs.
Fundamentals
| P/E | 36.60 |
| Forward P/E | 23.35 |
| PEG | 1.25 |
| P/B | 2.42 |
| EV/EBITDA | 10.40 |
| P/S | 0.32 |
| ROE % | 6.89 |
| ROA % | 3.90 |
| Gross margin % | 13.65 |
| Operating margin % | 3.46 |
| Net margin % | 0.88 |
| Revenue growth % (y/y) | 26.20 |
| Earnings growth % (y/y) | 27.10 |
| Revenue CAGR % | 11.77 |
| Earnings CAGR % | -24.91 |
| Debt/Equity % | 76.48 |
| Current ratio | 1.74 |
| FCF yield % | 0.81 |
| Dividend yield % | 92.00 |
| Payout % | 33.46 |
Returns
| 1 month | +0.3 % |
| 3 months | -2.6 % |
| 6 months | +133.6 % |
| YTD | +47.4 % |
| 1 year | +53.4 % |
| 3 years | -18.8 % |
| 5 years | +1.5 % |
Risk
| 1-year volatility | 47.2 % |
| Beta | 0.39 |
| 5-year max drawdown | -69.9 % |
| Sharpe 1A | 1.06 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.